Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety, tolerability, and pharmacokinetics of AZD1613 in adults with autosomal dominant polycystic kidney disease is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• AZD1613

Snippet

Sponsor: AstraZeneca | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 1 | Status: RECRUITING